- ROUNDTABLE: Pharmacy’s future in sync with technology
- Sandoz starts late-stage trial of Humira biosimilar
- EXPERT BLOG: Provider status for pharmacists — one way or another
- New Rite Aid group VP pharmacy initiatives and clinical services to oversee Wellness Ambassador program
- Kathleen Sebelius cites pharmacists' importance as Rite Aid CEO introduces Obamacare resource program
NEW YORK — Royalty Pharma will not buy Irish drug maker Elan Corp., the company said Tuesday.
Royalty said it would withdraw a request for a review by the Irish Takeover Panel after Elan shareholders voted in favor of a share buyback. Elan said last week that it would begin a process of selling itself to Royalty, which had previously offered $13 per share for the company.
Royalty, based in New York, invests in royalty interests in drugs already on the market and undergoing late-stage clinical trials. Its portfolio includes 80% of Memorial Sloan-Kettering Cancer Center's royalty on Amgen's Neupogen (filgrastim) and Neulasta (pegfilgrastim), for which it paid $400 million, and the AstraZeneca's royalties on AbbVie's drug Humira (adalimumab), which it bought for $700 million.